McKesson Ventures Joins Series C Round for Evariant

McKesson Ventures, the healthcare services and information technology arm of McKesson Corp., has made an investment in Evariant, a Farmington, Connecticut-based company that provides customer-relationship management technology to hospitals and health systems.

This investment in Evariant is the 11th for McKesson Ventures, which aims to support companies that catalyze or benefit from major shifts in healthcare. 

Evariant disclosed a $42.3 million Series C round late last year. McKesson’s investment adds to that number, though the total amount of the round remains undisclosed. Also participating in the round were Goldman Sachs, Health Enterprise Partners, Lightspeed Venture Partners, and Salesforce Ventures.

McKesson has been paying close attention to the rise of high-deductible health plans, which help customers shop for efficient, effective healthcare providers. It has also been tracking the shift toward value-based payments, a system that rewards providers for helping patients get healthy and stay healthy.

Evariant helps health systems appeal to customers by creating digital-marketing campaigns and by engaging patients when they aren’t at the doctor’s office.

Health systems can become more consumer-centric by responding to trends in the industry and engaging the right people in a patient population. Health systems have relied too heavily on conventional marketing in the past, but Evariant can help health systems respond to trends by creating more specialized campaigns that lead to short-term returns on investment.

Similar investments by McKesson include Accolade, a concierge service that helps patients navigate the healthcare system, and Kyruus Inc., which matches patients to the right doctors.

Subscribers to WSJ Pro may read the full article about McKesson’s investment in Evariant at